Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Real-world analysis of treatment patterns and clinical outcomes in patients with newly diagnosed chronic lymphocytic leukemia from seven Latin American countries.
Journal: Hematology (Amsterdam, Netherlands)
Published: October 23, 2020
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 18, 2019
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.
Journal: Pharmaceutical research
Published: November 06, 2018
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.
Journal: British journal of haematology
Published: August 09, 2018
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
Journal: Leukemia
Published: February 12, 2018
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study.
Journal: Leukemia & lymphoma
Published: January 04, 2018
The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
Journal: Future oncology (London, England)
Published: June 06, 2014
Showing 1-11 of 11
Last Updated: 09/26/2026